Hanmi Pharma of South Korea announced its fourth major out-licensing this year, a $960 million deal with Janssen for a diabetes-obesity drug; Denmark's LEO Pharma paid $727 million for global rights to Astellas' dermatology assets; Medtronic and Sequoia Capital partnered on a $60 million investment fund to support China device startups; BioDuro, a China-US CRO, merged its US operations with Formex, a CMO located in San Diego; WuXi PharmaTech and Eli Lilly will collaborate to develop a Lilly cardiovascular drug in China; ASLAN Pharma of Singapore and Hyundai Pharm will jointly develop an ASLAN molecule for cancer in South Korea; China will once again allow IPOs after a four-month suspension to prop up stock prices; Cellular Biomedicine opened a GMP manufacturing facility in the PKUCare Industrial Park of Beijing; and Hutchison MediPharma started a US Phase I clinical trial of sulfatinib in patients with solid tumors.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
